PIK3CA and cervical cancer: All three patients treated with everolimus who achieved an objective response or disease stabilization that lasted longer than 6 months had a double alteration affecting the PI3K/AKT/mTOR pathway, whereas less than one half of nonresponder patients with breast and cervical cancer had a double alteration involving that pathway.